Susumu S. Kobayashi
Susumu S. Kobayashi
Beth Israel Deaconess Medical Center
Verified email at
Cited by
Cited by
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
S Kobayashi, TJ Boggon, T Dayaram, PA Jšnne, O Kocher, M Meyerson, ...
New England Journal of Medicine 352 (8), 786-792, 2005
Clinical features and outcome of patients with non–small-cell lung cancer who harbor EML4-ALK
AT Shaw, BY Yeap, M Mino-Kenudson, SR Digumarthy, DB Costa, ...
Journal of clinical oncology 27 (26), 4247, 2009
Caspases are activated in a branched protease cascade and control distinct downstream processes in Fas-induced apoptosis
H Hirata, A Takahashi, S Kobayashi, S Yonehara, H Sawai, T Okazaki, ...
The Journal of experimental medicine 187 (4), 587-600, 1998
CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib
DB Costa, S Kobayashi, SS Pandya, WL Yeo, Z Shen, W Tan, KD Wilner
Journal of Clinical Oncology 29 (15), e443-e445, 2011
BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations
DB Costa, B Halmos, A Kumar, ST Schumer, MS Huberman, TJ Boggon, ...
PLoS medicine 4 (10), e315, 2007
EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications
H Yasuda, S Kobayashi, DB Costa
The lancet oncology 13 (1), e23-e31, 2012
Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non–small-cell lung cancers dependent on the epidermal growth factor receptor pathway
KSH Nguyen, S Kobayashi, DB Costa
Clinical lung cancer 10 (4), 281-289, 2009
The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies
H Ji, D Li, L Chen, T Shimamura, S Kobayashi, K McNamara, U Mahmood, ...
Cancer cell 9 (6), 485-495, 2006
Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer
H Yasuda, E Park, CH Yun, NJ Sng, AR Lucena-Araujo, WL Yeo, ...
Science translational medicine 5 (216), 216ra177-216ra177, 2013
Differential effects of gefitinib and cetuximab on non–small-cell lung cancers bearing epidermal growth factor receptor mutations
T Mukohara, JA Engelman, NH Hanna, BY Yeap, S Kobayashi, ...
Journal of the National Cancer Institute 97 (16), 1185-1194, 2005
Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance
GN Naumov, MB Nilsson, T Cascone, A Briggs, O Straume, LA Akslen, ...
Clinical Cancer Research 15 (10), 3484-3494, 2009
An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor
S Kobayashi, H Ji, Y Yuza, M Meyerson, KK Wong, DG Tenen, B Halmos
Cancer research 65 (16), 7096-7101, 2005
EGFR-mutated lung cancer: a paradigm of molecular oncology
Z Zhang, AL Stiegler, TJ Boggon, S Kobayashi, B Halmos
Oncotarget 1 (7), 497, 2010
Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers
DB Costa, S Kobayashi, DG Tenen, MS Huberman
Lung Cancer 58 (1), 95-103, 2007
Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib
DB Costa, KSH Nguyen, BC Cho, LV Sequist, DM Jackman, GJ Riely, ...
Clinical cancer research 14 (21), 7060-7067, 2008
Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells
Z Zhang, S Kobayashi, AC Borczuk, RS Leidner, T LaFramboise, ...
Carcinogenesis 31 (4), 577-586, 2010
Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance
T Shimamura, D Li, H Ji, HJ Haringsma, E Liniker, CL Borgman, ...
Cancer research 68 (14), 5827-5838, 2008
Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors
S Kobayashi, HM Canepa, AS Bailey, S Nakayama, N Yamaguchi, ...
Journal of Thoracic Oncology 8 (1), 118-122, 2013
Caspases Mediate Tumor Necrosis Factor-–Induced Neutrophil Apoptosis and Downregulation of Reactive Oxygen Production
K Yamashita, A Takahashi, S Kobayashi, H Hirata, PW Mesner Jr, ...
Blood, The Journal of the American Society of Hematology 93 (2), 674-685, 1999
Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer
H Yasuda, LL de Figueiredo-Pontes, S Kobayashi, DB Costa
Journal of Thoracic Oncology 7 (7), 1086-1090, 2012
The system can't perform the operation now. Try again later.
Articles 1–20